Business Context and Reporting Period
Company: NewAmsterdam Pharma Company N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2025
Reporting Period: Quarter ended June 30, 2025
Context: The filing announces corporate updates and financial results for the second quarter of 2025 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release containing corporate updates and financial results but does not include the text of that commentary.
Guidance and Outlook: No specific forward-looking guidance is detailed in the Form 8-K text.
Risks and Contingencies: No specific risks or contingencies are enumerated in the provided text.
Unusual Items: None identified in the filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 6, 2025) for actual revenue, net income, and cash position figures.
- Verify the specific nature of the "corporate updates" mentioned in the filing.
- Check for any new guidance or changes to the business strategy outlined in the press release.
- Confirm the status of the Company's ordinary shares (NAMS) and warrants (NAMSW) trading on The Nasdaq Stock Market LLC.